AbbVie has acquired rights to a multispecific antibody that IGI Therapeutics designed to bind to three targets to treat multiple myeloma. Early Phase 1 results showed encouraging responses in a heavily pretreated patient population and a favorable safety profile.
The post AbbVie Pays $700M for Drug Engineered to Overcome Resistance in Multiple Myeloma appeared first on MedCity News.
